Company intelligence / Profile preview

Quintessence Biotech

Madison, Wisconsin, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Quintessence Biosciences developed QBI-139, which was anticipated to enter Phase 1 clinical trials in the first half of 2008. The company focused on developing novel protein drugs for cancer treatment based on their EVade Ribonuclease technology.

Therapeutic areas: Oncology
Modalities: Protein-based therapeuticsRibonucleases
Industry: Biotech

Beyond the preview

Go deeper on Quintessence Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quintessence Biotech.

Explore the full profile